Explore more price target data and ratings for GeneDx Holdings Corp. on the Forecasts tab, and track all previous and future analyst recommendations for GeneDx Holdings Corp. in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This in…
Record Q2 volume and revenue exceeded guidance, with profitability achieved ahead of schedule. Strong demand and expanded payer coverage, especially for genome testing, set the stage for sustained growth, with significant improvements in collection rates and cash flow expected in late 2026 and 2027…
GeneDx reported second-quarter 2026 revenue of $114.4 million and GAAP net loss of $17.7 million, while adjusted net income was $0.4 million. Exome and genome revenue reached $100.3 million with result volumes up 32% year-over-year; adjusted gross margin was approximately 70%. The company reaffirme…
GeneDx Holdings Corp. reported second-quarter 2026 results with revenue of $114.4M, up from $102.7M a year earlier, while the company posted a net loss attributable to common stockholders of $(17.7)M and diluted EPS of $(0.60).Financial HighlightsBusiness HighlightsOriginal SEC Filing: GeneDx Holdi…
Q2 2026 saw 11% revenue growth to $114.4M, with exome/genome revenue up 17% and volumes up 32% year-over-year. Adjusted gross margin was 70%, and adjusted net income returned to positive territory. Full-year guidance was reiterated, and coverage expanded across Medicaid and commercial payers.Origin…
SAN FRANCISCO, July 29, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in GeneDx Holdings Corp. (NASDAQ:WGS) that a securities fraud class action lawsuit has been filed, and the firm is actively urging investors with substantial losses contact the firm now. The upcoming lead…
Lead Plaintiff Deadline: August 3, 2026SAN DIEGO, July 27, 2026 /PRNewswire/ -- Robbins LLP reminds investors that a securities class action has been filed on behalf of all persons and entities who purchased or otherwise acquired GeneDx Holdings Corp. (NASDAQ:WGS) common stock between April 16, 202…
SAN FRANCISCO, July 22, 2026 /PRNewswire/ -- Hagens Berman (HBSS), a national leader in securities litigation, is actively investigating claims in a securities class action lawsuit against GeneDx Holdings (NASDAQ:WGS) and its executives, alleging defendants misled investors about the Fabric Genomic…
Important Information Regarding Section 20(a) Individual Liability Claims Against GeneDx CEO and CFO for Alleged $33.42 Per-Share Investor Losses Tied to reimbursement weakness and underperformance of Fabric GenomicsNEW YORK, July 16, 2026 /PRNewswire/ -- SueWallSt alerts investors in GeneDx Holdin…
Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired GeneDx Holdings Corp. (NASDAQ: WGS) common stock between April 16, 2025 and May 4, 2026. GeneDx Holdings Corp is a genomics company that provides genetic testing services fo…
Firm is Securitizing Fabric Genomics AcquisitionSAN FRANCISCO, July 2, 2026 /PRNewswire/ -- Hagens Berman (HBSS), a national leader in securities litigation, is actively investigating claims in a securities class action lawsuit against GeneDx Holdings (NASDAQ:WGS) and its executives, alleging defen…
Firm is Securitizing Fabric Genomics AcquisitionSAN FRANCISCO, June 29, 2026 /PRNewswire/ -- Hagens Berman (HBSS), a national leader in securities litigation, is actively investigating claims in a securities class action lawsuit against GeneDx Holdings (NASDAQ:WGS) and its executives, alleging defe…
(14:17 GMT) GeneDx Holdings Price Target Raised to $74.00/Share From $70.00 by Guggenheim
